
    
      The main objective of this study is to determine the feasibility of maintaining virologic
      suppression on standard plasma viral load (limit of detection 37 copies / mL) of a dose
      reduction strategy of ATRIPLA Â® once a day to three tablets per week in patients infected
      with HIV-1 with sustained suppression of plasma viral load standard for more than two years.
    
  